Project Grant R01MH143270
- Grant Award Summary The National Institute of Mental Health (NIMH) awarded Columbia University's Health Sciences Division a Project Grant totaling $751,490 under the Mental Health Research Grants program (CFDA 93.242) for the period April 1, 2026, through March 31, 2029. This project, titled "Optimizing Use of Clinical Decision Support Tools to Enhance and Scale Delivery of Long-Acting Injectables for HIV Prevention and Treatment," develops and evaluates a comprehensive resource...
- Federal Grant Award Summary Modulo Bio, Inc. received a $1.48 million Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), awarded March 1, 2026, with a completion date of February 29, 2028. The award funds the development of an artificial intelligence (AI)-guided triculture platform designed to model HIV-associated brain injury (HABI) under antiretroviral therapy (ART) suppression. The platform will integrate induced...
- Federal Project Grant Award Summary The National Institute of Mental Health awarded The Miriam Hospital a $705,322 Project Grant on September 16, 2025, under the Mental Health Research Grants program (CFDA 93.242) to develop and evaluate CHIA (Chatbot for HIV Prevention and Action), an artificial intelligence-based behavioral intervention designed to improve pre-exposure prophylaxis (PrEP) adoption among men who have sex with men (MSM) in Ending the HIV Epidemic (EHE) jurisdictions. The...
- This federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $873,570 to Vanderbilt University Medical Center to create and evaluate synthetic data for multinational HIV cohorts. The project aims to develop advanced artificial intelligence methods to generate synthetic data that closely resembles the characteristics of original HIV cohort data, while severing the linkage between records and real...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded the University of North Carolina at Chapel Hill $691,620 under the Mental Health Research Grants program (CFDA 93.242) on September 22, 2025, for a three-year project period concluding September 21, 2028. This Project Grant funds the development and pilot testing of an online decision support system designed to increase Pre-Exposure Prophylaxis (PrEP) awareness and utilization among women in the Southeastern...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded The Johns Hopkins University a Project Grant totaling $149,190 under the Mental Health Research Grants program (CFDA 93.242) on August 2, 2026, with completion targeted for February 1, 2027. This research initiative, titled "Identifying Intervention Opportunities in the Continuum of Cognitive Impairment Among Persons Aging with HIV," produces epidemiological research and evidence synthesis designed to...
- Federal Grant Award Summary The University of Florida received a $289,868 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 22, 2025, through December 31, 2027. The award funds research to develop and apply phylodynamic and causal artificial intelligence (AI) methodologies for characterizing and predicting multi-drug resistant (MDR) bacterial transmission patterns within and...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded the University of North Carolina at Chapel Hill a Project Grant of $793,185 under the Mental Health Research Grants program (CFDA 93.242) to conduct research on HIV reservoir stabilization through inactivation of the Integrated Stress Response (ISR)/Activating Transcription Factor 4 (ATF4) signaling pathway. The research, which commenced April 7, 2026, and extends through January 31, 2031, aims to develop...
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $1.37 million Project Grant from the National Institute of Mental Health under the Mental Health Research Grants program (CFDA 93.242) effective September 23, 2025, through September 22, 2028. The grant funds the "RELAI" (Reaching Persons with HIV Who Are Out of Care Through Expedited Access to Long-Acting Injectable Antiretroviral Therapy) study, which evaluates field-based delivery of long-acting...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Johns Hopkins University a $145,299 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 1, 2025 through July 31, 2029. This award supports the development of novel Bayesian causal structural discovery and reinforcement learning methods to advance precision medicine in HIV care, specifically addressing the challenge of designing...
Grant Award Summary The University of Florida received a $1.13 million Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) to develop the Synchronized Agentic Prescriptive System for Improving Sequentially HIV Care Continuum (SYNAPSIS-HIV-CC). The award, effective April 1, 2026, through December 31, 2030, funds the development of an artificial intelligence (AI)-driven clinical decision support system designed to optimize HIV care outcomes across multiple health dimensions. The system integrates AI agents, large language models, and knowledge graphs to deliver individualized healthcare recommendations while addressing critical gaps in traditional machine learning approaches, which typically focus on single outcomes and lack human-interpretable explanations. SYNAPSIS-HIV-CC will generate human-interpretable, causally-reasoned clinical tools that monitor multiple HIV health endpoints, including loss of care, viral suppression, CD4 count levels, development of acute events, and comorbidity progression. The project also includes development of an antiretroviral regimen optimization system based on causal AI methodologies. Research activities are structured around three specific aims: agentic AI for multimodal prediction of multiple HIV outcomes; a multi-endpoint antiretroviral regimen optimization system; and implementation strategy refinement through qualitative expert assessment. Healthcare providers, including infectious disease specialists and community health experts, will be engaged in designing clinical applications to ensure practical utility for infectious disease clinicians.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.1m | 3/26/26 |